Skip to content

Comparison of efficacy between two modalities of treatment in diffuse hairloss.

Efficacy of autologous platelet rich plasma(PRP) versus growth factor concentrate(GFC) in moderate androgenetic alopecia: a randomized open-label trial - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089408
Enrollment
70
Registered
2025-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified Health Condition 2: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: platelet rich plasma (PRP): PRP and GFC will be done every month (minimum of 4 sessions) PRP Two PRP tubes with anticoagulant citrate dextrose (ACD) will be taken. 7ml of p

Sponsors

Dr Yogindher Singh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with androgenetic alopecia (Hamilton-Norwood grade 2-4; Ludwigs scale grade 1 and 2)

Exclusion criteria

Exclusion criteria: Patients age less than 18 years. Patients with infective and inflammatory scalp dermatoses. Patients with scarring alopecia. Patients with blood diathesis. Patients on treatment for AGA in last 3 months.

Design outcomes

Primary

MeasureTime frame
Primary outcomes Global photographic assessment of improvement at the vertex and frontal view. Graded 1 to 7 as dense, moderate, minimal regrowth and dense, moderate, minimal, no loss. First three grades were considered as responders and latter four as non responders. From baseline to 16 weeks terminal hair count, total hair density, proportion of anagen hairs will be assessed and documented. Timepoint: Primary outcomes Global photographic assessment of improvement at the vertex and frontal view. Graded 1 to 7 as dense, moderate, minimal regrowth and dense, moderate, minimal, no loss. First three grades were considered as responders and latter four as non responders. From baseline to 16 weeks terminal hair count, total hair density, proportion of anagen hairs will be assessed and documented.

Secondary

MeasureTime frame
Secondary outcomes as subject satisfaction with hair fall, hair density & texture on a scale of 1-10 . Timepoint: every 3rd week

Countries

India

Contacts

Public ContactDr Yogindher singh

Sri Venkateshwaraa medical college hospital

yogindher4@gmail.com06382353526

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026